Fecal calprotectin is a strong predictive marker of relapse in Chinese patients with Crohn’s disease: a two-year prospective study

References

• Peyrin-Biroulet L, Ferrante M, Magro F, et al. Results from the 2nd Scientific Workshop of the ECCO. I: impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis. 2011;5:477–483.
   PubMed Web of Science ®Google Scholar
• Manceau H, Chicha-Cattoir V, Puy H, et al. Fecal calprotectin in inflammatory bowel diseases: update and perspectives. Clin Chem Lab Med. 2017;55:474–483.
   PubMed Web of Science ®Google Scholar
• Chatzikonstantinou M, Konstantopoulos P, Stergiopoulos S, et al. Calprotectin as a diagnostic tool for inflammatory bowel diseases. Biomed Rep. 2016;5:403–407.
   PubMed Web of Science ®Google Scholar
• Tibble JA, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn’s disease. Gut. 2000;47:506–513.
   PubMed Web of Science ®Google Scholar
• Lasson A, Kilander A, Stotzer PO. Diagnostic yield of colonoscopy based on symptoms. Scand J Gastroenterol. 2008;43:356–362.
   PubMed Web of Science ®Google Scholar
• Lasson A, Simrén M, Stotzer PO, et al. Fecal calprotectin levels predict the clinical course in patients with new onset of ulcerative colitis. Inflamm Bowel Dis. 2013;19:576–581.
   PubMed Web of Science ®Google Scholar
• Wright EK, Kamm MA, De Cruz P, et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn’s disease after surgery. Gastroenterology. 2015;148:938–947.
   PubMed Web of Science ®Google Scholar
• Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut. 2005;54:364–368.
   PubMed Web of Science ®Google Scholar
• Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119:15–22.
   PubMed Web of Science ®Google Scholar
• Zhulina Y, Cao Y, Amcoff K, et al. The prognostic significance of fecal calprotectin in patients with inactive inflammatory bowel disease. Aliment Pharmacol Ther. 2016;44:495–504.
   PubMed Web of Science ®Google Scholar
• De Vos M, Louis EJ, Jahnsen J, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis. 2013;19:2111–2117.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Shimoyama T, Matsumoto K. Consecutive monitoring of fecalcalprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis. Aliment Pharmacol Ther. 2015;42:549–558.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Shimoyama T, Bamba T, et al. Consecutive monitoring of fecal calprotectin and lactoferrin for the early diagnosis and prediction of pouchitis after restorative proctocolectomy for ulcerative colitis. Am J Gastroenterol. 2015;110:881–887.
   PubMed Web of Science ®Google Scholar
• Riley SA, Mani V, Goodman MJ, et al. Microscopic activity in ulcerative colitis: what does it mean?. Gut. 1991;32:174–178.
   PubMed Web of Science ®Google Scholar
• Mendall MA, Chan D, Patel R, et al. Fecal calprotectin: factors affecting levels and its potential role as a surrogate marker for risk of development of Crohn's disease. BMC Gastroenterol. 2016;7:16–126.
   Google Scholar
• Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2–6.
   PubMedGoogle Scholar
• Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's disease activity index (CDAI)). Gastroenterology. 1979;77:843–846.
   PubMed Web of Science ®Google Scholar
• Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc. 2004;60:505–512.
   PubMed Web of Science ®Google Scholar
• Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105:162–169.
   PubMed Web of Science ®Google Scholar
• Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–753.
   PubMed Web of Science ®Google Scholar
• Canani RB, Terrin G, Rapacciuolo L, et al. Fecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis. 2008;40:547–553.
   PubMedGoogle Scholar
• Langhorst J, Elsenbruch S, Koelzer J, et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103:162–169.
   PubMed Web of Science ®Google Scholar
• Jones J, Loftus EV, Jr Panaccione R, et al. Relationship between disease activity and serum and fecal biomarkers in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2008;6:1218–1224.
   PubMed Web of Science ®Google Scholar
• Lin WC, Wong JM, Tung CC, et al. Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients. WJG. 2015;21:13566–13573.
   PubMed Web of Science ®Google Scholar
• D'Incà R, Dal Pont E, Di Leo V, et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol. 2008;103:2007–2014.
   PubMed Web of Science ®Google Scholar
• García-Sánchez V, Iglesias-Flores E, González R, et al. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?. J Crohns Colitis. 2010;4:144–152.
   PubMed Web of Science ®Google Scholar
• Kallel L, Ayadi I, Matri S, et al. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study. Eur J Gastroenterol Hepatol. 2010;22:340–345.
   PubMed Web of Science ®Google Scholar
• Sun S, Cavey T, Peltier L, et al. Letter: wide variation in faecal calprotectin values according to the assay. Aliment Pharmacol Ther. 2016;43:177–178.
   PubMed Web of Science ®Google Scholar
• Kopylov U, Rosenfeld G, Bressler B, et al. Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:742–756.
   PubMed Web of Science ®Google Scholar
• Marshall T, Lancashire R, Sharp D, et al. The diagnostic performance of scoring systems to identify symptomatic colorectal cancer compared to current referral guidance. Gut. 2011;60:1242–1248.
   PubMed Web of Science ®Google Scholar
• Elias SG, Kok L, de Wit NJ, et al. Is there an added value of fecal calprotectin and haemoglobin in the diagnostic work-up for primary care patients suspected of significant colorectal disease? A cross-sectional diagnostic study. BMC Med. 2016;26:14–141.
   Google Scholar